Status:
COMPLETED
Ceftobiprole in the Treatment of Resistant Staphylococcus Aureus Skin and Skin Structure Infections
Lead Sponsor:
Basilea Pharmaceutica
Conditions:
Skin Diseases, Infectious
Skin Diseases, Bacterial
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
The purpose of this study is to compare the clinical cure rate of ceftobiprole medocaril versus a comparator in the treatment of patients with complicated skin and skin structure infections.
Detailed Description
Ceftobiprole medocaril is a cephalosporin antibiotic with anti-MRSA (Methicillin-Resistant Staphylococcus Aureus) activity. Ceftobiprole medocaril is not yet approved for the treatment of complicated ...
Eligibility Criteria
Inclusion
- Diagnosis of an infection consistent with complicated skin and skin structure infections.
Exclusion
- Known or suspected hypersensitivity to any study medication
- Any known or suspected condition or concurrent treatment contraindicated by the prescribing information
- Previous enrollment in this study
- Treatment with any investigational drug within 30 days before enrollment.
Key Trial Info
Start Date :
October 1 2004
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2005
Estimated Enrollment :
784 Patients enrolled
Trial Details
Trial ID
NCT00228982
Start Date
October 1 2004
End Date
December 1 2005
Last Update
July 26 2012
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.